Given the propensity for triple‐negative breast cancer with BRCA1 mutations, as anticipated, most of the identified mutations were in BRCA2; therefore, the findings may be less applicable to BRCA1‐associated breast cancers. This evidence concerns the gene BRCA2 and breast cancer.